About
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.
Visit company website
5 years, 4 months ago
Ascletis Pharma Inc is currently in a long term uptrend where the price is trading 17.3% above its 200 day moving average.
From a valuation standpoint, the stock is 82.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.8.
Ascletis Pharma Inc's total revenue sank by 96.8% to $3M since the same quarter in the previous year.
Its net income has dropped by 223.7% to $-158M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.1% to $-34M since the same quarter in the previous year.
Based on the above factors, Ascletis Pharma Inc gets an overall score of 2/5.